| Monoclonal Antibodies |
Target |
Medical Use |
| OKT3 |
CD3 antigens on T-lymphocytes |
Acute rejection of transplanted kidneys, hearts and
livers |
| Abciximab |
GP IIb/IIIa on platelets |
Anti-thrombotic applications |
| Rituximab |
CD20 receptors on B lymphocytes |
Non-Hodgkin’s lymphoma |
| Daclizumab |
Interleukin-2 receptors on activated T
lymphocytes |
Acute rejection of transplanted kidneys |
| Trastuzumab (Herceptin) |
HER-2 growth factor receptors |
Advanced breast carcinomas expressing HER-2
receptors |
| Inflixibmab |
TNF (tumour necrosis factor) |
Rheumatoid arthritis and Crohn’s disease |
| Basiliximab |
Interleukin-2 receptors on activatedT
lymphocytes |
Acute rejection of transplanted kidneys |
| Palivizumab |
F protein of respiratory syncytial virus (RSV) |
RSV infection in children |
| Gemtuzumab |
CD33 antigen |
Relapsed acute myeloid leukemia |
| Alemtuzumab |
CD52 antigen on B and T lymphocytes |
B-cell chronic lymphocytic leukaemia |
| Cetuximab |
EGFR (epidermal growth factor receptor) |
Colorectal carcinoma and some other tumours |